SKYRIZI® receives positive reimbursement recommendations for ulcerative colitis in Canada, following support from clinical evidence and patient feedback.
Quiver AI Summary
AbbVie has announced that SKYRIZI® (risankizumab), an IL-23 inhibitor, has received two positive reimbursement recommendations from Canada's Drug Agency (CDA-AMC) for treating inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis (UC). This recommendation allows for public drug plans to reimburse SKYRIZI® for adults with moderately to severely active UC who have not adequately responded to other treatments. The recommendations were based on clinical trial evidence and input from healthcare professionals and patient organizations. Additionally, AbbVie has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance to facilitate access to this treatment for Canadian patients. The announcement underscores the need for effective therapies for UC, a condition that affects approximately 120,000 Canadians.
Potential Positives
- SKYRIZI® received positive reimbursement recommendations from Canada’s Drug Agency, enhancing access to treatment for ulcerative colitis for many patients.
- Completion of negotiations with the pan-Canadian Pharmaceutical Alliance for SKYRIZI® indicates strong collaboration and support for its use in treating ulcerative colitis.
- The press release highlights AbbVie's commitment to improving patient access to innovative therapies, aligning with the needs expressed by healthcare professionals and patient organizations.
Potential Negatives
- The reimbursement recommendation comes with conditions, which implies that access to SKYRIZI® may be limited for some patients and may not result in widespread availability immediately.
- Although negotiations with the pCPA were successful, the need to negotiate indicates potential pricing pressures and may reflect challenges faced by the company in positioning SKYRIZI® competitively in the market.
- The need for additional treatment options for ulcerative colitis indicates that current therapies may not be adequately addressing the needs of all patients, potentially impacting the perception of AbbVie's existing therapies.
FAQ
What is SKYRIZI® used for?
SKYRIZI® (risankizumab) is used to treat adults with moderately to severely active ulcerative colitis and Crohn's disease.
What are the recent updates regarding SKYRIZI® in Canada?
Recent updates include positive reimbursement recommendations for Skyzizi for ulcerative colitis and successful negotiations with the pCPA.
Who supports the recommendation for SKYRIZI®?
The recommendation for SKYRIZI® was supported by feedback from 25 Canadian clinicians and patient organizations like the GI Society.
What is ulcerative colitis?
Ulcerative colitis is a chronic inflammatory bowel disease causing inflammation and ulceration of the colon's lining, leading to severe symptoms.
How does SKYRIZI® work?
SKYRIZI® is an IL-23 inhibitor that specifically targets inflammatory processes associated with chronic diseases like ulcerative colitis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 6 times. They made 3 purchases worth up to $45,000 on 10/30, 07/22, 06/17 and 3 sales worth up to $45,000 on 10/31, 10/30, 07/22.
- SENATOR JOHN BOOZMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/22, 08/11.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 08/04.
- REPRESENTATIVE RITCHIE TORRES sold up to $15,000 on 07/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ABBV Insider Trading Activity
$ABBV insiders have traded $ABBV stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- AZITA SALEKI-GERHARDT (EVP, CHIEF OPERATIONS OFFICER) sold 42,370 shares for an estimated $8,407,055
- NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) has made 0 purchases and 2 sales selling 13,295 shares for an estimated $2,639,252.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ABBV Hedge Fund Activity
We have seen 1,924 institutional investors add shares of $ABBV stock to their portfolio, and 1,653 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 10,559,645 shares (+72.3%) to their portfolio in Q3 2025, for an estimated $2,444,980,203
- WELLINGTON MANAGEMENT GROUP LLP added 8,646,424 shares (+457.4%) to their portfolio in Q3 2025, for an estimated $2,001,993,012
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 3,134,454 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $725,751,479
- CAPITAL INTERNATIONAL INVESTORS removed 2,947,890 shares (-21.6%) from their portfolio in Q3 2025, for an estimated $682,554,450
- NORGES BANK removed 1,992,983 shares (-7.9%) from their portfolio in Q2 2025, for an estimated $369,937,504
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,830,775 shares (-53.6%) from their portfolio in Q3 2025, for an estimated $423,897,643
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 1,771,612 shares (+37.5%) to their portfolio in Q3 2025, for an estimated $410,199,042
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ABBV Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/20/2025
- Piper Sandler issued a "Overweight" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/15/2025
- BMO Capital issued a "Outperform" rating on 09/12/2025
To track analyst ratings and price targets for $ABBV, check out Quiver Quantitative's $ABBV forecast page.
$ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 14 analysts offer price targets for $ABBV in the last 6 months, with a median target of $250.5.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $220.0 on 11/07/2025
- David Amsellem from Piper Sandler set a target price of $289.0 on 11/05/2025
- Geoff Meacham from Citigroup set a target price of $235.0 on 11/03/2025
- Chris Schott from JP Morgan set a target price of $260.0 on 11/03/2025
- Vamil Divan from Guggenheim set a target price of $242.0 on 10/20/2025
- Gary Nachman from Raymond James set a target price of $250.0 on 10/17/2025
- Geoff Meacham from B of A Securities set a target price of $251.0 on 10/03/2025
Full Release
- SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC). 1,2
- AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI ® for UC. 3
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).
Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI ® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met. 2
The CDA-AMC’s positive recommendation was informed by feedback from 25 Canadian clinicians and two patient organizations, including the GI Society and Crohn’s and Colitis Canada, ensuring that the voices of those living with UC were considered.
AbbVie has also successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI ® for UC and a Letter of Intent (LOI) has been signed by both parties. 3
“UC can be an incredibly debilitating disease and patients need effective, safe treatment options that can help restore quality of life,” said Dr. Christopher Ma, MD, MPH, FRCPC, Cumming School of Medicine, University of Calgary. “This is a positive step towards ensuring that Canadians living with UC have access to treatments options that can help them achieve remission and improve their long-term outlook.”
“We are delighted that the Common Drug Review recommends that the public formularies cover the costs of an additional therapeutic option for ulcerative colitis. This new treatment is so desperately needed,” said Gail Attara, CEO of the Gastrointestinal Society, a patient group known by its badgut.org website. “Individuals living with UC are all different, requiring personalized treatment. Having a new therapy offers more hope and a chance to improve the quality of life by alleviating some symptoms.”
“This is a testament to the mutual commitment of AbbVie and the Health Authorities to improve patient access to innovative medicines for inflammatory bowel disease,” said Rami Fayed, Vice President and General Manager, AbbVie Canada. “AbbVie in Canada is encouraged by the opportunity to work in collaboration with the CDA-AMC and the pCPA throughout this process to provide access to innovative solutions that has the potential to impact eligible patients’ lives.”
About Ulcerative Colitis
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon’s lining. Common symptoms include frequent diarrhea, abdominal pain, and rectal bleeding, which can lead to significant impacts on patients’ daily lives, emotional wellbeing, and productivity. Approximately 120,000 Canadians are estimated to live with UC, and its prevalence continues to rise across the country. 4
About SKYRIZI ® (risankizumab) 1
SKYRIZI ® (risankizumab) is a humanized monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a key cytokine involved in inflammatory processes. SKYRIZI ® is indicated for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies. SKYRIZI ® is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to conventional therapy, biologic treatment, or a Janus kinase (JAK) inhibitor.
SKYRIZI ® is approved in Canada for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the treatment of adult patients with active psoriatic arthritis and it can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
For more information about AbbVie, please visit us at
www.abbvie.ca
.
Follow AbbVie Canada on X , Instagram , or LinkedIn .
Sources
- SKYRIZI (risankizumab) product monograph. AbbVie Corporation. Available at: https://pdf.hres.ca/dpd_pm/00081208.PDF
- Canada’s Drug Agency. Risankizumab (Skyrizi) Reimbursement Recommendation. Available at: https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0890-Skyrizi_Rec.pdf
- https://www.pcpacanada.ca/activity-overview
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6512240/
Media Inquiries:
Hind Mahreche
AbbVie Canada
514-348-8175
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1c2cb145-6311-40c1-ab45-e6a67513b221
